Working… Menu
Trial record 1 of 1 for:    hmi-102
Previous Study | Return to List | Next Study

Gene Therapy Clinical Study in Adult PKU (pheNIX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03952156
Recruitment Status : Recruiting
First Posted : May 16, 2019
Last Update Posted : July 26, 2019
Information provided by (Responsible Party):
Homology Medicines, Inc

Tracking Information
First Submitted Date  ICMJE May 9, 2019
First Posted Date  ICMJE May 16, 2019
Last Update Posted Date July 26, 2019
Estimated Study Start Date  ICMJE July 2019
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 14, 2019)
  • Incidence and severity of treatment-emergent adverse events (TEAE) and serious TEAEs [ Time Frame: Baseline to Week 52 ]
    Subjects with at least one TEAE or serious TEAE
  • Incidence of sustained reduction in plasma Phe concentration [ Time Frame: Baseline to Week 24 ]
    Subjects achieving a sustained plasma Phe concentration ≤360 μmol/L.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03952156 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 14, 2019)
  • Plasma Phe Concentration [ Time Frame: Baseline to Week 52 ]
    Change in plasma Phe concentration from baseline
  • Incidence of achieving a plasma Phe concentration to ≤360 μmol/L [ Time Frame: Baseline to Week 52 ]
    Subjects achieving plasma Phe concentration ≤360 μmol/L at each time point during the study.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: May 14, 2019)
Phenylketonuria Quality of Life Questionnaire (PKU-QOL) [ Time Frame: Baseline to Week 52 ]
Change in PKU-QOL
Original Other Pre-specified Outcome Measures Same as current
Descriptive Information
Brief Title  ICMJE Gene Therapy Clinical Study in Adult PKU
Official Title  ICMJE A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency
Brief Summary This is a Phase 1/2, open-label, randomized, concurrently-controlled, dose escalation study to evaluate the safety and efficacy of HMI-102 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of HMI-102 and will be followed for safety and efficacy for 1 year.
Detailed Description This study will evaluate the safety and efficacy of HMI-102 gene therapy in adult subjects with PKU due to PAH deficiency. Subjects will receive a single dose of HMI-102 administered intravenously. Up to 3 dose levels of HMI-102 may be investigated in this study. At a given dose level, a minimum of 2 subjects will be enrolled and dosed. Dosing of the first two subjects will be staggered. Following evaluation of data from the first 2 subjects in a cohort, a decision can be made to either escalate to the next dose level or expand the cohort at the selected dose level. If the cohort is expanded, additional subjects will be randomized to receive HMI-102 or a concurrent delayed treatment control arm. Subjects in the delayed treatment control will be eligible to receive HMI-102 after 24 weeks.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Phenylketonurias
  • PAH Deficiency
Intervention  ICMJE Genetic: HMI-102
HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
Study Arms  ICMJE
  • Experimental: Cohort 1
    Dose Level 1 of HMI-102 delivered intravenously one time
    Intervention: Genetic: HMI-102
  • Experimental: Cohort 2
    Dose Level 2 of HMI-102 delivered intravenously one time
    Intervention: Genetic: HMI-102
  • Experimental: Cohort 3
    Dose Level 3 of HMI-102 delivered intravenously one time
    Intervention: Genetic: HMI-102
  • No Intervention: Delayed Treatment Control
    Control subjects will generally have the same assessments as treated subjects. Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 14, 2019)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2021
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Adults 18-55 years of age at the time of informed consent
  • Diagnosis of classic phenylketonuria (PKU) due to PAH deficiency
  • Two plasma Phe values with a concentration of ≥ 600 μmol/L drawn at least 48 hours apart during the screening period and at least one historical value ≥ 600 μmol/L in the preceding 12 month.
  • Subject has the ability and willingness to maintain their baseline diet, whether Phe-restricted or unrestricted, after administration of HMI-102, unless otherwise directed

Key Exclusion Criteria:

  • Subjects with PKU that is not due to PAH deficiency
  • Presence of anti-AAVHSC15 neutralizing antibody
  • ALT >1.5x ULN and AST >1.5x ULN
  • Alkaline phosphatase >1.5x ULN.
  • Total bilirubin >1.5x ULN, direct bilirubin ≥ 1.5x ULN
  • Serum creatinine >1.5x ULN
  • Hematology values outside of the normal range (hemoglobin <11.0 g/dL for males or <10.0 g/dL for females; white blood cells (WBC) <3,000/μL; absolute neutrophils <1500/μL; platelets <100,000/μL)
  • Hemoglobin A1c >7.9% or fasting glucose >200 mg/dL
  • Any clinically significant abnormal laboratory result at screening, in the opinion of the Investigator
  • Contraindication to corticosteroid use or conditions that could worsen in the presence of corticosteroids, as assessed and determined by the investigator
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Steven Glyman, M.D. 781-819-0967
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03952156
Other Study ID Numbers  ICMJE HMI-102-101
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Homology Medicines, Inc
Study Sponsor  ICMJE Homology Medicines, Inc
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Homology Medicines, Inc
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP